R-HLH - Efficacy of Ruxolitinib as first line treatment in primary haemophagocytic lymphohistiocytosis (HLH) in children: a Phase 2, multicentre, non-comparative study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516105-23-01

Enrollment

Registered

2024-12-16

Start date

2024-11-10

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

haemophagocytic lymphohistiocytosis (HLH) in children

Brief summary

Survival until HSCT. All causes of death will be taken into account, whether or not related to the course of the disease.

Interventions

DRUGJakavi 15 mg tablets

DRUGJakavi 5 mg tablets

DRUGJakavi 10 mg tablets

DRUGJakavi 20 mg tablets

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Survival until HSCT. All causes of death will be taken into account, whether or not related to the course of the disease.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026